HCA Healthcare Reports Second Quarter 2023 Results
Raises 2023 GuidanceNASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE:HCA), today announced financial and operating results for the second quarter ended June...
Epidemics
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition...
Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
New U.S. patent provides intellectual property (IP) protection until December 2040, and may qualify for term extension beyond 2040There are...
Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in Adults
The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no...
Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of July 10, 2023
SCOTTSDALE, Ariz., July 03, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that...
Regional Health Properties, Inc. Announces Shareholder Approval of Special Meeting Proposals, Satisfaction of All Conditions to Exchange Offer and Preliminary Results of Exchange Offer
ATLANTA, GA, June 28, 2023 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (NYSE American: RHE) (NYSE American: RHE-PA) (“RHE” or...
Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
LONDON and RALEIGH, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”)...
Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association
Daix (France), Long Island City (New York, United States), June 24, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a...
Jasper Therapeutics Announces First Patient Dosed in a Phase 1 Trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome
REDWOOD CITY, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on...
Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors
Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor...
Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult Subjects
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that...
Jasper Therapeutics Announces Appointment of Edwin J. Tucker, M.D., as Chief Medical Officer
Accomplished Biotech and Large Pharma Executive to Lead Briquilimab Clinical Development Programs Daniel Adelman, M.D., Appointed to Scientific Advisory Board...
IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development
– Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in median third-line metastatic colorectal cancer...
Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023
Daix (France), Long Island City (New York, United States), May 26, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA),...
Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma
71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200...
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
Data from FGFRi-naïve FGFR2-fusion CCA patients represent subset of September 2022 presentation and remain consistent with previously reported resultsCAMBRIDGE, Mass.,...
Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations
Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double...
Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update
Announced Planned Development Expansion of Briquilimab in Chronic Spontaneous UrticariaPresented Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning...
Goodness Growth Holdings Closes on Initial $2.0 Million Tranche of $10.0 Million Financing Commitment
MINNEAPOLIS, May 01, 2023 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF),...
Vincerx Pharma Presents Preclinical Data on VIP236, a First-in-Class Small Molecule Drug Conjugate (SMDC), at the 2023 American Association for Cancer Research (AACR) Annual Meeting
VIP236, a SMDC with a novel optimized camptothecin (CPT) payload, demonstrated significant activity in patient-derived (PDX) mouse models and metastatic...